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LHP had approximately 713,000 person-
years of enrollment from 1993 to 1997. We
identified 104 members with a C. difficile
diagnosis on a claims record during this period.
This group includes most of the patients in our
original study. Most patients (62.5%) were
identified exclusively from inpatient records;
another 15.4% had both an inpatient and an
outpatient record with a C. difficile diagnosis;
and 22.1% had only an outpatient C. difficile
diagnosis. We calculated an age-adjusted rate of
infection (adjusted to the 1990 U.S. population),
for each year and for the 5-year period. The
incidence of C. difficile infection for all members
during 1993 to 1997 was 14.8 cases per 100,000
person-years of enrollment. The patients rates
for male and female were essentially the same
(14.4 vs. 15.5, respectively). The rates increased
dramatically with age. For persons ages 0-4, the
age-adjusted rate per 100,000 person-years of
enrollment (number of cases) was 5.3 (2); for 5-14,
2.7 (3), for 15-24, 2.2 (2); for 24-34, 6.4 (6); for 35-44,
9.2 (12); for 45-54, 15.7 (17); 55-64, 16.8 (10); 65-74,
38.5 (19); and 75+, 98.9 (33). The overall average
rate of infection was 15.4; there were 104 cases.
The rate of infection may have declined since
1993 in this population. The 1993 rate was 24.5
per 100,000 person-years of enrollment, declin-
ing to 11.1 in 1997 (1993, 24.4; 1994, 19.1; 1995,
9.9; 1996, 12.3; and 1997, 11.1).
Our method for estimating rates has some
limitations. We did not examine laboratory
records to confirm the diagnosis. In addition,
some laboratory-confirmed infections may not
have resulted in a claims record with a C. difficile
diagnosis. The Lovelace managed-care popula-
tion is an insured, generally healthy population
that may not have the characteristics of patients
in other health care delivery settings or, because
of its geographic restriction, the characteristics
of the general U.S. population. Nevertheless,
these estimates provide a basis for determining
the magnitude of the public health problem of C.
difficile infection. Additional surveillance stud-
ies are needed to better estimate the incidence of
infection and to determine whether the
incidence has declined during recent years.
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Diphtheria in Eastern Nepal
To the Editor: Diphtheria, caused by Corynebac-
terium diphtheriae, was a major childhood killer
until the advent of the Expanded Program on
Immunization when diphtheria, pertussis, and
tetanus (DPT) vaccination was greatly in-
creased; diphtheria gradually declined in many
countries. We report two cases of diphtheria
identified at the B.P. Koirala Institute of Health
Sciences Hospital, Dharan, Nepal.
During April 1996, a 6-year-old patient had
fever (for 5 days), difficulty in swallowing and
breathing, and change of voice (for 4 days).
Throat examination showed a grayish-white
membrane over the right tonsil, uvula, and
adjacent soft palate. The membrane could not be
removed, and the larynx could not be examined.
Swabs were taken from the membrane area and
sent to the laboratory, where smears were made
and stained by Gram and Albert stains. Gram-
stained smears showed a large number of gram-
positive bacilli with the appearance of Chinese
letters, and Albert stain showed bacilli with
numerous metachromatic granules. A diagnosis
of faucial diphtheria, with a strong possibility of
laryngeal diphtheria, was made. The patient was
treated with parenteral penicillin and diphtheria
antitoxin. His condition improved after 6 days of
therapy.
In December 1996, a 9-year-old patient
sought treatment for chronic pain and discharge
in the left ear. On examination, he had
mucopurulent discharge, antral perforation, and
mastoid tenderness. Throat examination showed
bilateral tonsilitis. A provisional diagnosis of
acute mastoiditis associated with acute septic
tonsillitis was made. Throat swabs were
collected and sent to the laboratory; smear
findings showed typical organisms morphologi-
cally resembling C. diphtheriae. Culture done on
10% defibrinated sheep blood agar and Loefflers
serum slope grew colonies consistent with
C. diphtheriae. In addition to local antibiotic to
the ear, the patient was given parenteral
penicillin, gentamicin, and metronidazole. Be-
cause the patient had no features of systemic
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toxicity, no antidiphtheria serum was adminis-
tered. The patient became well and was
discharged on day 4.
In the first case, a throat culture could not be
done because the patient had already received
local antiseptic paint. However, the diagnosis
was clinically consistent with classic diphtheria
with features of toxicity. In the second case,
diphtheria was suspected only after bacteriologic
examination. Unlike patient 1, patient 2 had no
evident features of systemic toxicity. Hence the
isolate could be nontoxigenic. Localized diphthe-
ria due to nontoxigenic C. diphtheriae is known
to occur (1).
The two patients did not give a complete
history of immunization and may not have been
vaccinated (or may have been partially
vaccinated) with DPT. On the Indian subconti-
nent, DPT vaccination coverage is reported to be
80%. However, it may not be so in all areas, and
immunization may have decreased to approxi-
mately 50% in certain areas of Southeast
Asia (2). This may also be true in certain areas of
eastern Nepal. An immunization status survey
done in midwestern Nepal from 1989 to 1990
showed that DPT coverage was unsatisfactory (3).
Lack of sustained immunization may even result
in outbreaks. The recent epidemics of diphtheria
in the Ukraine, Russian Federation, and other
countries of the former Soviet Union are
examples of resurgence due to ineffectively
maintained immunization programs (4,5).
Diphtheria, still occasionally seen in many
Southeast Asian countries including India and
Nepal, is thought to be declining in these areas.
However, accurate data have not been recently
available, particularly from Nepal, because
reporting is infrequent,  laboratory confirmation
is not available, and the extent of carriers is not
clearly known (2).
These two cases show the persistence of
diphtheria in a population in Nepal immunized
with DPT and underscore the need for careful
surveillance, laboratory documentation of clini-
cal diphtheria, and increased immunization of
children in this area.
H. Srinivasa, S.C. Parija, and M.P. Upadhyaya
B.P. Koirala Institute of Health Sciences,
Dharan, Nepal
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Commercial Use of Burkholderia cepacia
To the Editor: In their review of the potential
threat to human health by the commercial use of
Burkholderia cepacia, Holmes et al. (1) focus on
the biopesticidal uses of this bacterium in
agriculture. By virtue of its ability to antagonize
a number of soilborne plant pathogens,
B. cepacia is an attractive natural alternative to
currently used chemical pesticides, such as
captan, mancozeb, and metalaxyl. The replace-
ment of these highly toxic agents, which are
among the mainstays of crop protection
chemicals, by safer products is a laudable goal.
However, despite being nonpathogenic to
healthy humans (and thus classified as a Biosafety
Level 1 species), B. cepacia can cause life-
threatening pulmonary infection in persons with
cystic fibrosis. Holmes et al. call for a moratorium
on the use of B. cepacia in agriculture until more
is known about risks from such use.
Perhaps of greater concern than agricultural
use is B. cepacias use as a bioremedial agent.
Holmes et al. only briefly refer to the capacity of
this species to degrade chlorinated aromatic
substrates such as those found in certain
pesticides and herbicides. By virtue of its
extraordinary metabolic versatility, B. cepacia
can use such compounds as nutrient carbon
energy sources. In addition, some strains
produce enzymes capable of degrading
nonnutritive substrates, such as trichloroethyl-
